New 3D Mammography at Holy Cross offers better chance to diagnose breast cancer earlier, at more treatable stages
Holy Cross is excited to offer 3D mammography (breast tomosynthesis) for breast cancer screening at the Dorothy Mangurian Comprehensive Women’s Center. Breast tomosynthesis produces a three-dimensional view of the breast tissue that helps radiologists identify and characterize individual breast structures without the confusion of overlapping tissue.
The center’s Selenia® Dimensions® breast tomosynthesis system is made by Hologic, a world leader in digital mammography. The Selenia Dimensions system offers exceptionally sharp breast images, an advanced ergonomic design providing more patient comfort, and the ground-breaking tomosynthesis platform designed to deliver superior screening and diagnostic performance for all breast types. 1
“Holy Cross is committed to continually seeking ways to improve the patient experience and the advancement of women’s health,” said Howard Rubinson, MD, Diagnostic Radiologist. “We believe Breast Tomosynthesis will benefit screening and diagnostic mammography patients, while offering the greatest benefit to women with dense breasts.”
Breast cancer screening with tomosynthesis when combined with a conventional 2D mammography has a 40% higher invasive cancer detection rate than conventional 2D mammography alone.2-4 Tomosynthesis technology gives radiologists increased confidence with up to a 40% reduction in recall rates. 4-5
The tomosynthesis screening experience is similar to a traditional mammogram. During a tomosynthesis exam, multiple, low-dose images of the breast are acquired at different angles. These images are then used to produce a series of one-millimeter thick slices that can be viewed as a 3D reconstruction of the breast.
By offering women the latest and accurate6 technology in mammography, Holy Cross expects to increase the number of area women who will be routinely screened. Breast cancer is the second leading cause of cancer death among women, exceeded only by lung cancer. Statistics indicate that one in eight women will develop breast cancer sometime in her lifetime. The stage at which breast cancer is detected influences a woman’s chance of survival. If detected early, the five-year survival rate is 98 percent.7
Holy Cross Hospital is committed to the fight against breast cancer. In offering breast tomosynthesis digital mammography, Holy Cross provides the latest in imaging technology. If you would like to schedule a mammogram, please call 954-202-0277.
If you have questions about this important breast health procedure, please contact Linda Hamilton, Patient Navigator, at 954-351-4773.
1 Rafferty E, Park J, Philpotts L, et al. “Assessing Radiologist Performance Using Combined Digital Mammography and Breast Tomosynthesis Compared with Digital Mammography Alone: Results of a Multicenter, Multireader Trial.” Radiology. 2013 Jan; 266(1):104-13. Epub 2012 Nov 20.
2 Skaane P, Bandos A, Gullien R, et al. “Comparison of Digital Mammography Alone and Digital Mammography Plus Tomosynthesis in a Population-based Screening Program.” Radiology. 2013 Apr; 267(1):47-56. Epub 2013 Jan 7.
3 Ciatto S, Houssami N, Bernardi D, et al. “Integration of 3D Digital Mammography with Tomosynthesis for Population Breast-Cancer Screening (STORM): A Prospective Comparison Study” The Lancet Oncology. 2013 Jun;14(7):583-589. Epub 2013 Apr 25.
4 Rose S, Tidwell A, Bujnock L, et al. “Implementation of Breast Tomosynthesis in a Routine Screening Practice: An Observational Study.” American Journal of Roentengenology. 2013 Jun; 200(6): 1401-1408. Epub 2013 May 22.
5 Haas B, Kalra V, Geisel, J et al. “Comparison of Tomosynthesis Plus Digital Mammography and Digital Mammography Alone for Breast Cancer Screening.” Radiology. 2013 Jul 30. [Epub ahead of print].
6Zuley M, Bandos A, Ganott M, et al. “Digital Breast Tomosynthesis versus Supplemental Diagnostic Mammographic Views for Evaluation of Noncalcified Breast Lesions.” Radiology. 2013 Jan; 266(1):89-95. Epub 2012 Nov 9.
7 Breast Cancer Facts & Figures 2011, American Cancer Society.